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During  the  late  stage  of  the  viral  life  cycle,  HIV-1  Gag  assembles  into  a spherical  immature  capsid,  and
undergoes  budding,  release,  and  maturation.  Here  we  review  events  involved  in immature  capsid  assem-
bly from  the  perspective  of ﬁve  different  approaches  used  to  study  this  process:  mutational  analysis,
structural  studies,  assembly  of  puriﬁed  recombinant  Gag,  assembly  of  newly  translated  Gag in  a  cell-
free  system,  and  studies  in  cells  using  biochemical  and  imaging  techniques.  We summarize  key ﬁndings
obtained  using  each  approach,  point  out  where  there  is  consensus,  and  highlight  unanswered  questions.
Particular  emphasis  is placed  on reconciling  data  suggesting  that  Gag  assembles  by  two  different  paths,
depending  on  the  assembly  environment.  Speciﬁcally,  in  assembly  systems  that  lack  cellular  proteins,
high  concentrations  of Gag  can  spontaneously  assemble  using  puriﬁed  nucleic  acid as  a scaffold.  How-
ever,  in the more  complex  intracellular  environment,  barriers  that limit  self-assembly  are  present  in
the  form  of cellular  proteins,  organelles,  host  defenses,  and  the absence  of  free  nucleic  acid.  To over-
come  these  barriers  and  promote  efﬁcient  immature  capsid  formation  in  an unfavorable  environment,
Gag  appears  to utilize  an  energy-dependent,  host-catalyzed,  pathway  of  assembly  intermediates  in  cells.
Overall,  we show  how  data  obtained  using  a variety  of  techniques  has  led  to  our  current  understanding
of  HIV  assembly.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
.1. Overview
One of the remarkable features of HIV-1 is its proliﬁc abil-
ty to generate new virus particles. Estimates suggest that up to
010 virions are produced per day in an infected individual (Chun
t al., 1997), leading to levels of viremia as high as 107 virions per
illiliter of blood (Perelson et al., 1996). This prodigious ability can
e attributed to the impressive capacity for virus production: it is
stimated that an HIV-1 infected cell produces ∼5 × 104 virions in a
ingle day, which is the estimated lifespan of an infected cell (Chen
t al., 2007). These numbers reﬂect in part the remarkable efﬁciency
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adukdik@uw.edu (K. Chutiraka), robinsob@u.washington.edu (B.A. Robinson).
ttp://dx.doi.org/10.1016/j.virusres.2014.07.001
168-1702/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
of the late events in the virus life cycle within the infected cell. These
numbers also speak to the importance of understanding, at a cel-
lular and molecular level, why  late events such as assembly are so
efﬁcient within cells. And yet, as described below, important puz-
zle pieces are missing from our picture of how HIV-1 assembles in
infected cells.
Late events in the virus lifecycle can be divided into 4 main
stages: (1) Gag polyprotein assembly, which leads to formation of
the HIV-1 immature capsid (also called the immature lattice); (2)
budding and envelopment of the immature capsid; (3) immature
virus particle release; and (4) maturation into the infectious virus,
which involves cleavage of the Gag polyprotein by the HIV-1 pro-
tease into its four constituent domains. This review focuses entirely
on the ﬁrst stage – assembly of the HIV-1 immature capsid lat-
tice, the spherical protein shell that is located within the immature
virus and encapsidates the viral genome. It is well accepted that
HIV-1 has evolved sophisticated mechanisms for taking advantage
of the host cell at many stages of replication in order to efﬁ-
ciently generate progeny virus. While mechanisms for co-opting
host machinery have been described in detail for virus budding
and release (reviewed in Votteler and Sundquist, 2013), equivalent
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
9 s Rese
m
a
i
c
a
t
i
p
i
c
t
m
i
b
H
a
J
1
m
t
n
h
g
m
e
F
d
s
b
g
c
p
i
m
a
w
H
l
i
v
b
l
(
I
t
G
r
2
c
t
p
B
d
i
o
1
m
a
i
i0 J.R. Lingappa et al. / Viru
echanisms for co-opting host proteins during immature capsid
ssembly remain poorly understood. Identifying and understand-
ng how HIV-1 utilizes cellular machinery during capsid assembly
ould offer novel approaches for inhibiting virus production in
ctively infected cells, as well as in cells reactivated out of latency.
In this section we summarize the current view of HIV-1 imma-
ure capsid assembly within cells. In subsequent sections we
llustrate how different experimental systems have yielded com-
lementary pieces of the HIV-1 assembly puzzle, while highlighting
mportant questions that remain unanswered and concepts that
ould reconcile contrasting assembly models. Other topics related
o HIV-1 assembly have been reviewed elsewhere and will only be
entioned here in passing, including gRNA trafﬁcking and packag-
ng (reviewed in Kuzembayeva et al., 2014; Lu et al., 2011), HIV-1
udding and release (reviewed in Votteler and Sundquist, 2013),
IV-1 maturation (reviewed in Sundquist and Krausslich, 2012),
nd the subcellular localization of HIV-1 assembly (reviewed in
ouvenet et al., 2008; Klein et al., 2007).
.2. The current view of HIV-1 assembly in cells
The 55 kDa HIV-1 Gag polyprotein contains four domains –
atrix (MA), capsid (CA), nucleocapsid (NC), and p6 – as well as
wo small spacer peptides, SP1 and SP2 (Fig. 1). When deﬁned
arrowly, the problem of immature capsid assembly is about
ow ∼1500–3000 Gag polyproteins multimerize to form a sin-
le immature capsid shell. Viewed from this limited perspective,
any questions related to assembly appear resolved since the gen-
ral functions of the major domains in Gag are well understood.
or example, mutational analyses reveal that only the ﬁrst three
omains of Gag (MA, CA, and NC) are required for immature cap-
id assembly per se,  with the fourth domain, p6, being required for
udding and release. Additionally, it is well established that MA
overns membrane targeting; CA contains residues that form criti-
al Gag–Gag interactions; and NC is required for viral genomic RNA
ackaging as well as non-speciﬁc interactions with RNA. However,
n infected cells, the process of immature capsid assembly is much
ore complex than would be suggested by a simple Gag-centric
nd domain-centric view of Gag function. To provide perspective,
e start here with an overview of our current understanding of
IV-1 assembly, aspects of which are discussed in more detail
ater.
Gag is the only viral protein required for assembly and release of
mmature virus particles in cells, although production of infectious
irus requires other viral proteins. Assembly of the Gag polyprotein
egins in the cytoplasm of the infected cell, where Gag is trans-
ated from a full-length capped and polyadenylated genomic RNA
gRNA), and is co-translationally myristoylated at its N-terminus.
mportantly, the full-length gRNA species is both the mRNA used for
ranslation of Gag and the genome that is packaged by assembling
ag. How the pool of full-length gRNA serves for both purposes
emains poorly understood (reviewed in Butsch and Boris-Lawrie,
002; Kuzembayeva et al., 2014; Lu et al., 2011). While in the
ytoplasm, newly synthesized Gag undergoes limited oligomeriza-
ion (Kutluay and Bieniasz, 2010), associates with the gRNA it will
ackage (Jouvenet et al., 2009; Kemler et al., 2010; Kutluay and
ieniasz, 2010), and also associates with several cellular factors, as
escribed below.
Because the plasma membrane (PM) is the site of virion release
n most cells (Jouvenet et al., 2006), trafﬁcking of the initial Gag
ligomer from the cytoplasm to the PM is a critical step in HIV-
 assembly. Membrane targeting of Gag requires the N-terminal
yristate, as well as residues in MA  that form a basic patch
nd interact with acidic head groups of phospholipids in the PM,
ncluding phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] found
n the inner leaﬂet of the PM (reviewed in Chukkapalli and Ono,arch 193 (2014) 89–107
2011). Structural studies have shown that the myristate is initially
sequestered within a cavity formed by the globular domain of MA
(Tang et al., 2004) (Fig. 2A). Regulatory mechanisms control the
timing of myristate exposure to ensure that membrane targeting
occurs after Gag has associated with gRNA, formed an oligomer, and
is in close proximity to the PM (reviewed in Chukkapalli and Ono,
2011). Additionally, live imaging studies reveal that membrane tar-
geting by Gag is responsible for anchoring gRNA at the PM (Jouvenet
et al., 2009). Once at the PM,  Gag continues to multimerize by a
mechanism that is poorly understood; and while assembly is still
in progress, the viral bud begins to form, thereby initiating the next
stage in the viral life cycle.
Studies reveal that Gag proteins are not alone when they
oligomerize in the cytoplasm, trafﬁc to the PM,  and multimerize
at the PM.  Shortly after translation, Gag co-opts a cytoplasmic host
complex that contains RNA granule proteins (also called processing
body or P body proteins) (Reed et al., 2012). Two of the proteins in
this complex are host enzymes that facilitate assembly – ABCE1
and DDX6 (Reed et al., 2012; Robinson et al., 2014; Zimmerman
et al., 2002). A third co-opted host protein, Staufen, is an RNA
binding protein that facilitates Gag multimerization and RNA pack-
aging (reviewed in Cochrane et al., 2006). Exactly how these cellular
facilitators act remains to be determined, but studies have found
that Gag remains with these proteins as it trafﬁcs to the PM and
multimerizes. These studies have revealed that Gag progresses
through a sequential pathway of assembly intermediates, which
are described by their sedimentation values (∼10S, ∼80S, ∼150S,
and ∼500S). The high-molecular-mass assembly intermediates (the
∼80S, ∼150S, and ∼500S complexes) contain gRNA and other viral
proteins, as well as cellular proteins, such as ABCE1 and DDX6,
that dissociate when assembly is completed (Dooher et al., 2007;
Reed et al., 2012; Robinson et al., 2014; Zimmerman et al., 2002).
Consistent with this model, assembly-defective Gag mutants are
arrested at speciﬁc steps in this assembly pathway, resulting in
accumulation of the assembly intermediates that precede the point
of blockade (Fig. 3). Thus, assembly can be viewed from the per-
spective of Gag, or from the perspective of the cellular proteins
that the virus hijacks to assist Gag in its journey through the cell.
Both the assembly pathway and cellular facilitators of assembly are
viewed as controversial by some. This is not surprising given the
complexities of biochemical studies in cells; additionally, it may  be
too soon to assess the full impact of these studies. Nevertheless, the
assembly pathway is included in this review because it forms the
cornerstone of a fundamentally different approach to understand-
ing assembly – in which Gag is viewed as one of many players in
the poorly understood intracellular environment – that contrasts
with the Gag-centric approach that currently dominates the ﬁeld.
At the end of assembly, the completed immature capsid is
released. In structural studies of the completed immature cap-
sid, CA forms a hexameric lattice that contains irregular defects to
accommodate the spherical shape (Bharat et al., 2012, 2014; Briggs
et al., 2009; Carlson et al., 2010; de Marco et al., 2010; Fuller et al.,
1997; Keller et al., 2011; Wright et al., 2007). Residues that form
key CA-CA interfaces in the immature capsid lattice are starting to
be identiﬁed with some precision in increasingly high-resolution
structures (Bharat et al., 2012, 2014). Such interfaces are present
in the fully assembled immature capsid and likely form when
Gag multimerizes. Notably, many of the residues that form CA-CA
interfaces in the immature capsid are also required for efﬁcient
immature capsid assembly (Bharat et al., 2012, 2014; Robinson
et al., 2014). Recent biochemical studies in cells have deﬁned when
these and other critical residues act during assembly, leading to
a model for the temporal sequence in when each of these critical
CA-CA interfaces are formed (Robinson et al., 2014).
While many experimental approaches have contributed to our
current understanding of immature capsid assembly in cells, here
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Fig. 1. HIV-1 Gag domain map  and amino acid sequence showing residues critical for immature capsid assembly. (A) Schematic showing domains, subdomains, and spacer
peptides in Gag [MA  (red), CA-NTD (green), CA-CTD (blue), SP1 (pink), NC (orange), SP2 (light gray) and p6 (dark gray)]. The highly conserved MHR motif is highlighted
in  purple. Also shown is minimal Gag, a construct containing the minimal domains needed for assembly (Accola et al., 2000), in which some domains or subdomains are
deleted (horizontal black lines), NC is replaced with a leucine zipper (LZ, light orange), and p6 is replaced with a short peptide containing the RSV PPPPY motif (medium gray).
(B)  Amino acid sequence of HIV-1 LAI Gag, with amino acid numbering for the complete Gag polyprotein shown above, and numbering for individual domains and spacer
peptides (MA, CA, SP1, NC, and SP2) shown below. Note that the text and other ﬁgures in this review use the domain number system. Black lines indicate domain boundaries.
The  12 actual or predicted -helices in CA/SP1 are enclosed in black boxes (H1-H12). Residues that are critical for immature capsid assembly are color-coded by surface (see
legend).  Colored lines above the critical residues indicate assembly-defective phenotypes produced by single (|) or double ( ) residue mutations; brackets indicate regions in
w type.
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e focus on ﬁve approaches that have shaped our thinking about
ssembly in complementary ways. The ﬁrst of these, mutational
nalysis of virus production (Section 2), was the main approach
sed in early studies of assembly. The second approach, structural
iology (Section 3), has been used for nearly 30 years, with recent
dvances leading to increasingly higher resolution. The third and
ourth approaches – assembly of puriﬁed recombinant Gag and
ssembly of newly synthesized Gag in cell extracts (Sections 4 and
) – involve in vitro systems that were developed in the 1990s
nd offer two very different views of the assembly process. Finally,
n the past 10–15 years, a variety of tools have been devised to
tudy events of assembly in cells, including live imaging as well
s biochemical, ultrastructural, and siRNA-based approaches for
dentifying critical viral-host interactions (Section 6).ˆ
2. Effects of mutations in Gag on virus production
2.1. Overview
For over three decades, HIV-1 assembly has been studied by
infecting or transfecting cells to express a mutated virus, and
assessing the resulting phenotype. Because the Gag protein acts
during many stages of the HIV life cycle, replication-defective Gag
mutations fall into multiple categories depending on the point
at which the viral life-cycle is inhibited. For example, some Gag
mutations cause defects in post-entry events (e.g. uncoating or
nuclear trafﬁcking of the pre-integration complex) but do not affect
the amount of virus produced. Other Gag mutations inhibit virus
release or maturation but not virus assembly. Here we  will focus on
92 J.R. Lingappa et al. / Virus Research 193 (2014) 89–107
Fig. 2. Models for the structure of HIV-1 Gag domains and the architecture of the immature capsid. (A) Ribbon diagrams of myristoylated MA  in red (1UPH.pdb); full-length
CA  (3NTE.pdb) based on crystal structures of the individual CA-NTD and CA-CTD domains, shown in green and blue, respectively; SP1 (hypothetical -helix) shown in pink,
and  NC (1MFS.pdb) shown in orange. Regions that contain residues critical for immature capsid assembly (shown in Fig. 1B) are indicated with brackets or arrows. Black
highlights show locations of relevant amino acids. Dotted line shows ﬂexible linker between MA  and CA. (B) Schematic of full-length Gag as shown in (C and D), with each
domain labeled. (C) “Beads on a string model” for the arrangement of the Gag polyprotein in the immature capsid, adapted from Fuller et al. (1997), Ganser-Pornillos et al.
(2008) and Yeager et al. (1998). (D) Model showing a hexameric conﬁguration for CA-NTD, CA-CTD, and SP1 in the context of the fully assembled immature capsid lattice at
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 category of Gag mutations that speciﬁcally inhibit immature cap-
id assembly (Figs. 1B and 2A). These mutations have little effect on
ag expression but cause signiﬁcant reductions in particle produc-
ion by inhibiting membrane targeting or multimerization of Gag at
embranes. To assess particle production, the amount of pelletable
irus-like particles present in the cell supernatant is measured
nder conditions in which steady-state levels of Gag are equiva-
ent between samples. To assess the amount of Gag targeting or
ultimerization at the PM,  biochemical studies are utilized, ideally
n conjunction with electron microscopy. While only well-studied
utations critical for immature assembly are discussed here, other
esidues in Gag may  also play a role.
.2. MA  residues required for immature capsid assembly in cells
The role of myristoylation and MA  residues in membrane target-
ng has been reviewed in detail elsewhere (Chukkapalli and Ono,
011). Brieﬂy, myristoylation involves recognition of a speciﬁc N-
erminal, six amino acid signal by a cytoplasmic enzyme, resulting
n co-translational addition of myristate, a 14-carbon saturated
atty acid, to the nascent polypeptide N-terminus (Wright et al.,
010). Myristoylation of Gag is required for membrane targetingof Gag and production of immature virus particles, as revealed by
the G2A mutation in MA,  which abrogates the myristoylation signal
in Gag (Bryant and Ratner, 1990; Gheysen et al., 1989; Gottlinger
et al., 1989) (Figs. 1B and 2A). Consistent with these ﬁndings, when
Gag is expressed at physiological levels, myristoylation of Gag is
also required for immature capsid assembly (Dooher and Lingappa,
2004; Klein et al., 2011; Robinson et al., 2014). Since membrane
targeting is thought to concentrate Gag, it is not surprising that the
dependence of assembly on myristoylation observed at physiolog-
ical levels of expression can be overcome by very high levels of Gag
expression. For example, when the G2A Gag mutant is expressed at
very high levels in insect cells, cytoplasmic capsid-like structures
are observed (Gheysen et al., 1989); such structures have not been
reported when G2A Gag is expressed in mammalian cells at levels
comparable to those seen in HIV-1 infection.
In N-myristoylated proteins, the myristate moiety can exist
in two  conformations – either sequestered within a hydrophobic
pocket or exposed. The transition between these states constitutes
a reversible “myristoyl switch” (McLaughlin and Aderem, 1995;
Resh, 2006). In full-length HIV-1 Gag, the myristate is sequestered
in a hydrophobic pocket created by -helices in MA  (Hermida-
Matsumoto and Resh, 1999; Ono and Freed, 1999; Paillart and
J.R. Lingappa et al. / Virus Research 193 (2014) 89–107 93
Fig. 3. Mutations of speciﬁc residues critical for immature capsid assembly cause arrest of Gag at distinct points in the assembly pathway in cells. In cells, HIV-1 Gag
progresses sequentially through an energy-dependent, stepwise pathway of assembly intermediates (∼10S, ∼80S, ∼150S, and ∼500S complexes) before forming the fully
assembled ∼750S immature capsid. To form the ∼80S intermediate, Gag co-opts a precursor complex that contains the cellular facilitators of assembly, ABCE1 and DDX6.
Mutations of residues critical for immature capsid assembly (shown in Fig. 1B) have been analyzed to determine the point at which they inhibit progression of Gag in the
HIV-1  capsid assembly pathway. As shown here, each mutation blocks the pathway at a characteristic point, with accumulation of assembly intermediates that precede the
point  of inhibition. Mutations can be divided up into 5 different classes, depending on where they block the assembly pathway, as indicated in red boxes. Dotted lines indicate
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ottlinger, 1999; Perez-Caballero et al., 2004; Saad et al., 2007;
pearman et al., 1997; Tang et al., 2004; Zhou and Resh, 1996), dis-
ussed further in Section 3.2. Mutational analyses demonstrated
hat a valine and leucine at positions 7 and 8 in MA  (V7 and L8)
re required for myristate exposure (Saad et al., 2007) and mem-
rane targeting (Freed et al., 1994; Ono and Freed, 1999; Ono et al.,
997, 2000; Paillart and Gottlinger, 1999). When analyzed at a more
etailed biochemical level in cells expressing the HIV-1 provirus,
utations of the myristoylation signal or the residues required for
yristate exposure cause Gag to be arrested at the second step in
he assembly pathway, with accumulation of the cytoplasmic ∼10S
nd ∼80S assembly intermediates (Robinson et al., 2014) (Class 2
utations in Fig. 3).
In keeping with the reversible nature of myristoyl switches,
yristoylation is thought to be necessary but not sufﬁcient for sta-
le membrane binding, with a second signal required to maintain
embrane binding (McLaughlin and Aderem, 1995; Resh, 2006). In
he case of Gag, the second signal is the highly basic region (HBR),
 patch of basic residues (spanning amino acids 15–32 in MA)  that
orm electrostatic interactions with the acidic head group of the
M phospholipid PI(4,5)P2 (Saad et al., 2006; Zhou et al., 1994;
hou and Resh, 1996) (Figs. 1B and 2A). Additionally, mutational
nalyses have shown that residues around amino acids 85–89 in
A are important for directing assembling Gag to the PM,  rather
han to internal membranes within the cell (Freed et al., 1994; Ono
t al., 2000). It is generally accepted that the PM is the main site
f infectious HIV-1 assembly (reviewed in Jouvenet et al., 2011a;
lein et al., 2007), although there may  be some situations in which
argeting virus to internal compartments can lead to productive
ssembly and release (Joshi et al., 2009). Thus, residues that directe in the text.
Gag to the PM during assembly typically ensure efﬁcient release of
infectious virus.
In summary, regions of the 132 amino acid MA domain that
are critical for proper Gag assembly in cells include: (i) residues
2–5 required for myristoylation; (ii) residues 7 and 8, required for
myristate exposure; (iii) the MA HBR, which stabilizes membrane-
targeted Gag through PI(4,5)P2 interactions; and (iv) residues
between amino acids 85–89, which ensure targeting of Gag specif-
ically to the PM (Figs. 1B and 2A).
2.3. CA and SP1 residues required for immature capsid assembly
in cells
The CA domain of Gag is composed of N-terminal and C-
terminal subdomains, termed CA-NTD (residues 1–145) and
CA-CTD (residues 146–231), respectively (Fig. 1B). In the con-
text of wild-type (WT) Gag both CA subdomains play important
roles in assembly, although CA-NTD is dispensable for assem-
bly of a minimal Gag construct (see Section 2.5). Altogether,
CA contains eleven -helices, with helices 1–7 in CA-NTD and
helices 8–11 in CA-CTD (Figs. 1B and 2A). In the case of CA-
NTD, alanine-scanning mutagenesis revealed that speciﬁc exposed
residue pairs in helices 4, 5, and 6 (EE75/76, RS100/102, TT107/108,
and TQ110/112, shown in Figs. 1B and 2A) promote efﬁcient assem-
bly and virus production in cells (von Schwedler et al., 2003).
Subsequent studies conﬁrmed a role for these CA-NTD residues dur-
ing immature capsid assembly, and demonstrated that mutations
of these residues inhibit the ﬁnal step in assembly, leading to accu-
mulation of all the intermediates in the assembly pathway with no
virion release (Class 5 mutations in Fig. 3) (Robinson et al., 2014).
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nterestingly, a recent structural study found that residues adjacent
o or near these four residue pairs form critical inter-hexameric CA-
TD interfaces in the completed immature capsid formed by CA-NC
f Mason-Pﬁzer monkey virus (MPMV) (Bharat et al., 2012). Thus,
hese residues are likely required during assembly because they
orm inter-hexameric CA-NTD contacts that stabilize the immature
apsid.
Residues in CA-CTD that are required for immature capsid
ssembly were initially identiﬁed through alanine-scanning muta-
enesis and deletion mapping (e.g. Borsetti et al., 1998; Dorfman
t al., 1994; Joshi et al., 2006; Mammano et al., 1994; Ono et al.,
005; von Schwedler et al., 2003). One set of CA residues crit-
cal for immature capsid assembly are located in CA helix 9
the second -helix in CA-CTD), which forms the crystallographic
A-CTD dimer interface (Fig. 2A). Assembly-defective CA-CTD
imer interface mutations are exempliﬁed by the WM184/185AA
utant (Joshi et al., 2006; Ono et al., 2005; von Schwedler et al.,
003).
A second set of CA residues critical for immature capsid assem-
ly is located at the base of the CA-CTD crystal structure, where
hree non-contiguous regions of CA are in close proximity: the
ajor homology region (MHR), CA helix 10, and the CA-CTD
ail (Figs. 1B and 2A). Examples of assembly-defective CA-CTD
ase mutations include K158A in the MHR; D197A in CA helix
0; and P224A, in the CA-CTD tail (von Schwedler et al., 2003)
Figs. 1B and 2A). Biochemical analyses examining the effect of CA-
TD mutations on the assembly pathway in cells reveal that the CA-
TD dimer interface residues stabilize the ﬁrst membrane-targeted
ssembly intermediate, while the CA-CTD base residues are
equired for continued multimerization of Gag at the PM (Robinson
t al., 2014) (Class 3 and 4 mutations respectively in Fig. 3).
Two of the three regions that form the CA-CTD base are of par-
icular interest. The ﬁrst is the MHR, a 20 amino acid motif that
recedes and overlaps with CA helix 8 (the ﬁrst -helix in CA-CTD,
ig. 1A). This motif is unusually well conserved, especially given
hat the amino acid sequence of the rest of Gag, with the excep-
ion of NC, is poorly conserved. The MHR  is required for replication
f retroviruses (Chang et al., 2007; Craven et al., 1995; Mammano
t al., 1994; Strambio-de-Castillia and Hunter, 1992; von Schwedler
t al., 2003; Willems et al., 1997) as well as the Ty3 retrotransposon
Orlinsky et al., 1996). Mutations of conserved residues in the HIV-
 MHR  inhibit immature capsid assembly, although when and how
hey act remains unclear (Chang et al., 2007; Mammano et al., 1994;
on Schwedler et al., 2003). Thus, the function of the MHR  during
ssembly is not yet understood, and is likely a critical missing piece
f the assembly puzzle, given its high degree of conservation.
The second region of interest at the base of CA is the CA-CTD
ail, which is disordered in the CA-CTD crystal structure (Gamble
t al., 1997). Secondary structure prediction programs, NMR, and
iophysical analyses reveal that the C-terminus of CA-CTD, along
ith the adjacent SP1 spacer, can form an -helix (Accola et al.,
998; Datta et al., 2011; Morellet et al., 2005; Newman et al., 2004)
shown as helix 12 in Fig. 2A). These studies have led to the proposal
hat an intact helix 12 may  be critical for assembly of full-length
ag, but is lost upon cleavage. Consistent with this hypothesis,
umerous mutational analyses reveal that residues in SP1 are criti-
al for virus particle production (Chu et al., 2006; Gross et al., 2000;
uo and Liang, 2005; Guo et al., 2005; Krausslich et al., 1995; Liang
t al., 2002, 2003).
In summary, mutational analyses indicate that three regions of
A are required for immature capsid assembly: helices 4–6 in CA-
TD, the CA-CTD dimer interface in helix 9, and the three regions
hat form the CA-CTD crystallographic base (the MHR, helix 10, and
he CA-CTD tail). Related to the third region, an -helix that is pre-
icted to span the CA-CTD tail and SP1 also appears to be critical
or assembly of full-length Gag (Figs. 1B and 2A).arch 193 (2014) 89–107
2.4. The role of nucleocapsid in immature capsid assembly in cells
The NC domain of Gag contains two Cys-X2-Cys-X4-His-X4-
Cys (CCHC) motifs, also called Cys-His boxes, each of which
co-ordinates a zinc ion (reviewed in Freed, 1998). The NC Cys-
His boxes are critical for speciﬁc gRNA encapsidation (reviewed in
Berkowitz et al., 1996; Lu et al., 2011). Additionally, NC contains
15 basic residues dispersed throughout the domain (Fig. 1B). In
the context of WT Gag, NC is critical for Gag multimerization; this
requirement has been mapped to basic residues in NC (Cimarelli
et al., 2000; Dawson and Yu, 1998; Derdowski et al., 2004; Gheysen
et al., 1989; Jowett et al., 1992; Sandefur et al., 1998). The basic
residues at the N-terminus of NC [which form a region previously
termed the interaction (I) domain] also promote non-speciﬁc asso-
ciation of Gag with RNA, allowing RNA to bridge, tether, or scaffold
Gag; this is thought to increase the local concentration of Gag,
thereby indirectly promoting Gag–Gag interactions. As discussed in
Section 4, this model is supported by the ﬁnding that RNA promotes
multimerization of puriﬁed recombinant Gag in vitro (Campbell
and Rein, 1999; Campbell and Vogt, 1997). Thus, NC basic residues
mediate indirect, RNA-mediated Gag–Gag interactions, in contrast
to residues in CA helix 9 (in CA-CTD), which mediate direct Gag–Gag
dimerization. In cells, mutation of nine or more of the NC basic
residues results in severe defects in immature capsid assembly
(Cimarelli et al., 2000), causing Gag to be arrested at the ﬁrst step in
the assembly pathway with accumulation of only the ∼10S assem-
bly intermediate (Lingappa et al., 2006; Reed et al., 2012) (Class 1
mutation in Fig. 3). In contrast, the direct interactions mediated by
helix 9 are required for stable membrane targeting of assembling
Gag, later in the assembly pathway (Robinson et al., 2014) (Class 3
mutations in Fig. 3). Thus, these two  Gag–Gag interaction domains
– NC acting indirectly via RNA and CA helix 9 acting through direct
protein–protein interactions – function at very different points dur-
ing the assembly process.
2.5. Deﬁning the minimal domains required for Gag assembly
As described above, point mutations and deletions within indi-
vidual domains reveal that MA,  CA-NTD, CA-CTD, SP1, and NC
each play an important role in assembly of WT Gag. In a com-
plementary approach, mutational analyses were used to identify
Gag domains that are absolutely required for assembly (i.e. cannot
be either deleted or replaced). Domain replacement was initially
used to gain insights into the function of NC (Zhang et al., 1998). In
this study, immature capsid assembly and release was unaffected
when NC was  replaced with a heterologous transcription factor
leucine zipper, a canonical protein dimerization or trimerization
domain (Alber, 1992). The resulting GagZip particles contained lit-
tle RNA, since the leucine zipper does not bind nucleic acid, but
nevertheless were morphologically similar to immature particles
formed by WT Gag (Accola et al., 2000; Crist et al., 2009; Johnson
et al., 2002; Zennou and Bieniasz, 2006). Moreover, like WT  Gag,
GagZip proteins require the critical CA-CTD dimerization residues
(WM184/185) for assembly, interact with ABCE1, and form intra-
cellular assembly intermediates unless the leucine zipper domain is
mutated to inhibit dimerization (Klein et al., 2011). Thus, together
studies of GagZip proteins reveal that the function of NC in assembly
is to promote Gag–Gag interactions; that the role of NC in Gag mul-
timerization is independent of its role in gRNA packaging; and that
replacement of NC (which promotes indirect Gag–Gag interactions
via RNA) with a domain that forms direct protein–protein interac-
tions does not affect immature capsid assembly or progression of
Gag through ABCE1-containing assembly intermediates.
Another study extended this approach and demonstrated that
many of the remaining regions of Gag in the assembly-competent
GagZip protein could be either deleted or replaced without
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ffecting assembly (Accola et al., 2000). Thus, immature GagZip
apsids still form following removal of CA-NTD and most of MA
except for the N-terminal amino acids involved in myristoyla-
ion and myristate exposure). Additionally, the p6 domain can be
eplaced with a short peptide containing a budding motif from RSV
ag. In the resulting “minimal Gag” protein, the only regions of
IV-1 Gag that could not be deleted or replaced without adversely
ffecting assembly were CA-CTD and SP1 (and likely the myristoy-
ation signal) (Fig. 1A). Thus, these studies revealed that CA-CTD
nd SP1 are uniquely critical for assembly, for reasons that remain
nclear. Notably, as described above, CA-CTD contains the MHR,
 highly conserved and poorly understood motif required for
ssembly.
. Structural biology of Gag domains
.1. Overview of Gag structural biology
Cleavage of the Gag polyprotein by the HIV-1 protease occurs
imultaneous with, or just after, release of the immature virus.
ollowing cleavage, MA  (also called p17), CA (also called p24), NC
also called p7), p6, and the spacer peptides exist as independent
roteins, some of which play critical roles during the post-entry
hase of the virus life cycle. X-ray structures have been solved
or only three retroviral Gag domains or subdomains over the
ears: MA,  CA-NTD, and CA-CTD (reviewed in Ganser-Pornillos
t al., 2008, 2012). Because it is the Gag polyprotein that undergoes
ssembly, additional insight into how Gag functions during assem-
ly would be gained from a crystal structure of full-length Gag.
nfortunately, full-length Gag has eluded crystallization because it
ontains highly ﬂexible unstructured regions (Bharat et al., 2012),
ncluding the p6 domain, the spacer peptides, and the linker regions
hat connect the structured MA  domain and CA subdomains. The
rystal structures of MA,  CA-NTD, and CA-CTD have obvious rel-
vance to events that occur following maturation, but have also
elped with computationally generated structures of full-length
ag in the immature virion (Bharat et al., 2012; Briggs et al.,
009; Carlson et al., 2010; de Marco et al., 2010; Fuller et al.,
997; Keller et al., 2011; Wright et al., 2007). Nevertheless, in the
bsence of a high-resolution structure of full-length Gag, we are
eft with a gap in our understanding of structural considerations
uring early events of Gag assembly. Moreover, we are also faced
ith the nagging question of how infected cells handle the highly
exible, and possibly unstable, newly synthesized, full-length Gag
rotein.
Here we will discuss structures of MA,  CA-NTD, CA-CTD, the
A-SP1 boundary, and the fully assembled immature capsid. NMR
tructures are also available for NC complexed with individual stem
oops of the HIV-1 psi-element packaging signal (Amarasinghe
t al., 2000; De Guzman et al., 1998), but are not discussed here.
nterestingly, the three dimensional structures of MA,  CA-NTD, and
A-CTD are conserved in diverse retroviruses, despite very limited
verall amino acid sequence conservation (e.g. Bharat et al., 2012;
ampos-Olivas et al., 2000; Christensen et al., 1996; de Marco et al.,
010). Thus, the structures of MA  and CA appear to be highly
onstrained by their functions. Likewise, the architecture of fully
ssembled RSV, and MPMV  immature capsids is remarkably sim-
lar to that of HIV-1 (de Marco et al., 2010), which is described in
ection 3.5.
.2. Structure of the matrix (MA) domainIn high-resolution structures, the 132 amino acid MA  domain
ontains ﬁve -helices and a three-stranded mixed -sheet (Hill
t al., 1996; Massiah et al., 1994) (Fig. 2A). Helices 1–3 arerch 193 (2014) 89–107 95
organized around a central, buried helix 4 to form a globular domain
that is capped by the -sheet, with helix 5 projecting away from
the globular domain. MA forms a trimer when crystallized (Hill
et al., 1996), and a hexamer of trimers on membranes contain-
ing PI(4,5)P2 (Alfadhli et al., 2007, 2009). From the perspective of
immature capsid assembly, the two most important features of MA
are the cavity formed by the MA  globular domain and the basic
residues that cluster around the exposed MA -sheet and form the
aforementioned HBR.
NMR  studies show that the cavity formed by the globular
domain of MA can sequester the N-terminal myristate of MA
(Tang et al., 2004). In these studies, MA in solution exists both in
myristate-sequestered and myristate-exposed states. A shift in the
equilibrium toward the myristate-exposed state occurs upon Gag
oligomerization involving either direct (CA-CA-mediated) inter-
actions or indirect (NC-mediated) interactions, thereby coupling
myristate exposure to early oligomerization events. Additionally,
direct binding of MA to PI(4,5)P2 in the PM favors myristate
exposure as well as PM binding (Saad et al., 2006) (reviewed in
Ganser-Pornillos et al., 2012). In contrast, RNA binding to the MA
basic residues appears to inhibit myristate exposure in the context
of full-length Gag (Chukkapalli et al., 2010). Thus, myristate expo-
sure is governed by a number of positive and negative regulators,
perhaps including other cellular factors not yet described. By act-
ing in concert, these regulators likely allow RNA binding and Gag
oligomerization to precede membrane targeting (Chukkapalli and
Ono, 2011).
The HBR mediates electrostatic contacts with acidic phos-
pholipids (Zhou et al., 1994) such as PI(4,5)P2, which is found
preferentially in the PM inner leaﬂet, and thereby helps to anchor
assembling Gag to the PM.  Notably, studies suggest that the HBR-
PI(4,5)P2 interaction may  involve other elements, besides charge
alone (Chukkapalli et al., 2010; Llewellyn et al., 2013). NMR  stud-
ies indicate that HBR binding to PI(4,5)P2 promotes exposure of
the sequestered myristate, which in turn allows one PI(4,5)P2 acyl
chain to occupy a hydrophobic groove within the MA globular head,
while the other PI(4,5)P2 acyl chain remains anchored in the PM
(Saad et al., 2006). Thus, two hydrophobic interactions anchor Gag
to the PM:  the exposed myristate of Gag inserted into the PM inner
leaﬂet, and a PI(4,5)P2 acyl chain extending out of the lipid bilayer
to sit in an MA hydrophobic pocket (reviewed in Chukkapalli and
Ono, 2011).
3.3. Structure of the N-terminal and C-terminal domains of
capsid (CA-NTD and CA-CTD)
The immature Gag lattice is stabilized by direct Gag–Gag inter-
actions, the majority of which are in CA-NTD, CA-CTD, and SP1.
CA-NTD contains seven -helices that form an arrow shaped struc-
ture (Gamble et al., 1996; Gitti et al., 1996) (Fig. 2A). An extended
loop connects helices 4 and 5 and also forms the binding site for
cyclophilin A (Gamble et al., 1996), a host factor that acts post-entry,
during capsid uncoating (Luban, 2007). CA-CTD is composed of a
short 310 helix followed by an extended strand and four -helices
(numbered helices 8–11 in CA) (Gamble et al., 1997; Worthylake
et al., 1999). As discussed in Section 2.3, CA-CTD contains the
highly conserved 20 amino acid MHR  motif, which overlaps with
the strand-turn-helix 8 region at the N-terminus of HIV-1 CA-
CTD. The MHR  is required for immature capsid assembly of HIV-1,
other retroviruses, and the Ty3 retrotransposon (Chang et al., 2007;
Craven et al., 1995; Mammano et al., 1994; Orlinsky et al., 1996;
Strambio-de-Castillia and Hunter, 1992; von Schwedler et al., 2003;
Willems et al., 1997).
CA-CTD crystallizes as a side-by-side dimer, in which helix 9
forms the dimer interface, with hydrophobic contacts stabilizing
its interaction with its symmetry mate (Byeon et al., 2009; Gamble
9 s Rese
e
d
C
2
t
s
l
f
a
e
t
i
(
3
l
t
ﬁ
l
b
G
e
(
s
w
(
t
c
g
c
c
r
3
e
r
e
2
e
c
i
c
c
i
f
c
f
i
a
c
l
t
h
C
(
i
s
t
r
a
C6 J.R. Lingappa et al. / Viru
t al., 1997; Worthylake et al., 1999). A second “domain-swapped”
imer structure has been observed in crystal structures of a CA-
TD mutant in which a single amino acid was deleted (Ivanov et al.,
007). In this structure, the MHR  formed the interface between the
wo dimers. While the notion that Gag dimers adopt a domain-
wapped conformation during assembly of the immature capsid
attice is an appealing one (Kingston and Vogt, 2005), evidence in
avor of the domain-swapped conformation has not been gener-
ted by recent structural studies, including a deuterium hydrogen
xchange study (Monroe et al., 2010), a 17-Å structure of the imma-
ure HIV-1 capsid (Briggs et al., 2009), and 8 to 11-Å structures of
mmature capsid-like tubular arrays of MPMV  and HIV-1 CA-NC
Bharat et al., 2012, 2014).
.4. Structural studies of the SP1 spacer
As mentioned above, computational programs predict that the
ast seven residues of CA [which are disordered in the CA-CTD crys-
al structure (Gamble et al., 1997; Worthylake et al., 1999)] and the
rst seven residues of SP1 form an -helix in the context of full-
ength Gag (Accola et al., 1998). The helical propensity of CA-SP1
oundary is supported by mutational approaches (Chu et al., 2006;
ross et al., 2000; Guo and Liang, 2005; Guo et al., 2005; Krausslich
t al., 1995; Liang et al., 2002, 2003), biophysical and NMR  studies
Datta et al., 2011; Morellet et al., 2005; Newman et al., 2004), and
tructural analyses of the fully assembled immature capsid, all of
hich are consistent with this region forming a six helix bundle
Bharat et al., 2014; Wright et al., 2007). Interestingly, in studies of
he puriﬁed CA-SP1 peptide in buffer an abrupt switch to a helical
onformation was observed at high peptide concentrations, sug-
esting that this region is capable of a conformational switch that
ould promote assembly (Datta et al., 2011). Whether this helical
onformation is present when full-length Gag assembles in cells
emains to be determined.
.5. Structure of the immature capsid
Improvements in cryo-electron microscopy (cryoEM) and cryo-
lectron tomography (cryoET) have led to increasingly higher
esolution structures of the immature capsid in recent years (Bharat
t al., 2012; Briggs et al., 2009; Carlson et al., 2010; de Marco et al.,
010; Fuller et al., 1997; Keller et al., 2011; Wright et al., 2007). Oth-
rs have reviewed the structure of the immature capsid revealed by
ryoET studies in detail (Ganser-Pornillos et al., 2012). Brieﬂy, the
mmature capsid does not display icosahedral symmetry – unlike
apsids of other viruses – but instead is composed of a lattice that
ontains areas of hexagonal order, as well as defects that allow for
ts spherical shape. The generally hexagonal architecture comes
rom the CA-NTD, CA-CTD, and SP1 regions, each of which forms
losely packed hexameric structures. There is general consensus
rom cryoET and cryoEM studies that Gag within the completed
mmature capsid adopts an extended, radially arranged “beads on
 string” conﬁguration (Fig. 2B and C). In this conﬁguration, MA  is
losest to the viral membrane, with CA-NTD forming a hexameric
attice that sits below the MA  layer; below that is a hexameric lat-
ice formed by CA-CTD; and below the “hole” formed by the CA-CTD
examer are pillars of density formed by the putative helix at the
A/SP1 boundary, which has been modeled as a six helix bundle
Fig. 2D).
A recent 8-Å resolution cryoEM/cryoET structure of the
mmature-like tubular assemblies formed by MPMV  CA-NC deﬁned
ome of the residues in CA-CA interfaces (Bharat et al., 2012). In
his study, a ﬁtted reconstruction of the HIV-1 immature capsid
evealed that CA-NTD is stabilized by inter-hexameric contacts
lone, formed by residues in helices 4–7 in CA-NTD. In contrast,
A-CTD is stabilized by both intra- and inter-hexameric contacts inarch 193 (2014) 89–107
the immature capsid. Residues in CA helix 11 and the MHR  (which
overlaps with CA helix 8) contribute to intra-hexameric CA-CTD
interfaces, while residues in CA helix 9 form inter-hexameric CA-
CTD contacts at the hydrophobic dimer interface, in agreement with
numerous previous studies. Notably, this study found that inter-
face residues in the immature capsid differ substantially from the
interface residues in the mature capsid (Bharat et al., 2012). Indeed
the only interface in common was  the CA-CTD dimer interface,
which involves CA helix 9 in both the immature and mature cap-
sid, albeit in different orientations (Bharat et al., 2012). A follow-up
study used hybrid cryoEM/cryoET to resolve an ∼9–11-Å structure
of immature-like tubular assemblies composed of HIV-1 CA-NC
encoding a Y196 mutation that stabilizes these tubular assemblies
but does not affect crystal structure of CA domains (Bharat et al.,
2014). This structure conﬁrmed that CA-CTD dimers in MPMV and
HIV-1 immature assemblies are structurally similar, but found that
the size of the HIV-1 CA-CTD hexamer is smaller, resulting in more
extensive intra-hexameric CA-CTD contacts for HIV-1 via additional
residues in the MHR  and CA helix 11.
3.6. Gag structural biology: new horizons and challenges
As cryoEM/cryoET techniques improve, it is likely that increas-
ingly high-resolution structures of the fully assembled immature
capsid will be obtained in the future. Such structures will allow
more accurate mapping of residues involved in Gag–Gag interfaces,
thereby ﬁlling in more pieces of the puzzle. An example of the
degree of resolution that can be achieved is seen in a recent 8-
Å resolution cryoEM/cryoET structure of the mature HIV-1 capsid,
from which large scale molecular dynamics simulation resulted in
an all-atom model of an entire mature capsid (Zhao et al., 2013).
Ultimately, however, the biggest challenge for structural biologists
will be to obtain a structure of full-length Gag, and to better under-
stand structural considerations underlying the interaction of Gag
with cellular facilitators of assembly.
4. Assembly of recombinant Gag in vitro
4.1. Principles learned through studying the assembly of
recombinant Gag in vitro
To gain insights into the process of assembly, systems have
been generated that recapitulate capsid formation outside the con-
text of the cell. One such system involves studying self-assembly
of puriﬁed, isolated Gag domains (Fig. 4). In this system, puriﬁed
recombinant Gag is incubated at high concentrations (∼1 mg/ml,
or 20 M)  in buffer. Typically a recombinant MA-CA-NC protein
(Gagp6) is used, since including the unstructured p6 domain,
which contains motifs involved in budding, leads to degradation
in E. coli (Campbell and Rein, 1999). Additionally, the recombinant
proteins used in these systems are not myristoylated [myr(−)].
Incubation of recombinant HIV-1 myr(−)Gagp6 with RNA or
even oligonucleotides in buffer results in spherical structures that
resemble HIV-1 immature capsids, except for being signiﬁcantly
smaller (25–30 nm vs. 100 nm in diameter) (Campbell and Rein,
1999). Thus, these studies revealed that, in a simpliﬁed envi-
ronment, Gag has an intrinsic ability to assemble into spherical
structures in the presence of nucleic acid alone.
Subsequently it was shown that adding inositol phosphates
or phosphatidylinositol phosphates to the recombinant in vitro
assembly system results in capsid-like structures that are similar in
size to immature capsids produced in cells (Campbell et al., 2001).
This ﬁnding began with the observation that addition of a cellular
extract to recombinant assembly systems resulted in particles of
the correct size. Fractionation of this extract led to identiﬁcation
J.R. Lingappa et al. / Virus Research 193 (2014) 89–107 97
Fig. 4. Comparison of the pathways for assembly in the recombinant and cell-free assembly systems. (A) The recombinant assembly system contains puriﬁed nucleic acids,
an  inositol phosphate-related compound (IP), and a puriﬁed, fully folded, recombinant myr(−)Gagp6. In solution, myr(−)Gagp6 is thought to exist in a folded-over form.
Addition of IP and oligomerization of Gag converts Gag to an extended form resulting in formation of spherical structures that closely resemble HIV-1 immature capsids. The
only  intermediate in the pathway is likely a dimer. (B) In the cell-free system, as in cells, Gag progresses through an energy-dependent, host-catalyzed pathway of assembly
intermediates (∼10S, ∼80S, ∼150S, and ∼500S complexes), culminating in formation of the ∼750S completed immature capsid. A cellular extract and puriﬁed exogenous
components provide factors needed for Gag translation and assembly. RNAs are found in ribonucleoprotein complexes. Gag mRNA is translated by ribosomes from the extract
to  produce WT myristoylated Gag de novo. Newly synthesized Gag co-opts host proteins to form the assembly intermediates. Based on studies in the cell-free system and/or
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equired for progression past the ∼80S intermediate. References are in the text.
f an inositol phosphate that increased particle size when added
irectly to the recombinant reaction (Campbell et al., 2001). As
escribed in Section 6.3, studies in cells later led to identiﬁcation
f PI(4,5)P2, a PM-associated phosphatidylinositide that binds to
A in cells, and promotes proper membrane targeting (reviewed
n Chukkapalli and Ono, 2011).
The recombinant assembly of Gag-derived proteins has also
een useful for analyzing the architecture of the immature cap-
id (e.g. Bharat et al., 2012, 2014; de Marco et al., 2010), as
escribed in Section 3.5. Additionally, studies of puriﬁed recom-
inant myr(−)Gagp6 in vitro have deﬁned the behavior of
ag in solution. Biophysical measurements reveal that Gag is
n a monomer-dimer equilibrium in solution, and suggest that
onomeric Gag adopts a folded over conformation that brings MA
elatively close to CA (Datta et al., 2007). It remains to be deter-
ined if this folded-over structure is also found in cells. If so, then
ag must undergo a drastic conformational change via an unknown
echanism to achieve the extended conformation found in fully
ssembled particles. It has been suggested that such a conforma-
ional change could be achieved during oligomerization of Gag,
ased on in vitro studies (Datta et al., 2011). However, it is also pos-
ible that in cells Gag co-opts a host protein that either prevents Gag DDX6. Intact membranes, likely present as vesicles, and myristoylation of Gag are
from adopting the folded-over form, or facilitates conversion from
the folded-over to the extended form. Additionally, it is unclear
how the highly unstructured p6 domain, which was  not included
in these recombinant studies, might affect the folded-over confor-
mation of Gag in cells.
4.2. The recombinant Gag assembly system recapitulates a
simpliﬁed environment, not an intracellular environment
The in vitro capsid assembly system reconstitutes the process
of assembly in a very speciﬁc environment – one in which puriﬁed
Gag is present at very high concentrations (1 mg/ml or ∼20 M)
and puriﬁed RNA is available to nucleate assembly. This approach
established two  concepts that have dominated the ﬁeld: that RNA
nucleates the assembly of Gag (in conjunction with Gag–Gag and
Gag–lipid interactions); and that in the presence of nucleic acid Gag
can assemble spontaneously, i.e. uncatalyzed and without the input
of energy. To put these concepts into context, however, it must be
recognized that there are a number of key differences between the
recombinant assembly system and the intracellular environment.
First, in cells the concentration of Gag is likely much lower than in
the recombinant assembly system, and the concentration of total
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ellular protein is estimated to be very high – up to 200–400 mg/ml
Ellis, 2001). Both of these features would be expected to reduce
he frequency of spontaneous Gag–Gag interactions, making spon-
aneous assembly of Gag less likely in cells. Secondly, because RNA
s such a potent activator of the innate immune response (reviewed
n Gurtler and Bowie, 2013), viral RNA would likely not be present
n a puriﬁed form in cells, but instead would be sequestered within
ost ribonucleoprotein (RNP) complexes where RNA is shielded by
roteins. Thirdly, in cells HIV-1 must co-ordinate the many events
eeded to produce an infectious virus with great efﬁciency. For
xample, in cells Gag must ﬁnd the gRNA sequestered within a
ost RNP complex, remove the RNPs that coat the gRNA and replace
hem with Gag to promote encapsidation of gRNA – and succeed in
hese tasks rapidly with limited detection by the host.
Thus, given that the cytoplasm of infected cells is best described
s a hostile environment full of obstacles, Gag is unlikely to
ssemble spontaneously in cells the way it does in the simpli-
ed environment of the recombinant assembly system. Instead,
etroviral Gag proteins are likely to have developed specialized
echanisms to avoid detection and enhance assembly efﬁciency
n cells. A parallel can be seen in the study of protein folding.
peciﬁcally, Nobel prize-winning experiments in the 1960s demon-
trated that the primary amino acid sequence of a protein contains
ll the information needed for proper protein folding (Anﬁnsen,
973). And yet, we now know that because of the vectorial nature
f protein synthesis and the detrimental consequences of protein
ggregation, most protein folding in cells is facilitated by a diverse
rray of molecular chaperones – cellular proteins that assist pro-
ein folding in cells without becoming part of the protein’s ﬁnal
tructure (Hartl, 1996; Kim et al., 2013). If the same is true for Gag
ssembly, then the principle of “Gag self-assembly” revealed by
he recombinant assembly system would best be viewed as demon-
trating that Gag can self-assemble, not that Gag does self-assemble.
s discussed in Sections 5 and 6 below, systems that recapitulate
IV-1 assembly in the context of the cellular environment strongly
avor a model in which assembly in cells is energy-dependent,
ost-catalyzed, and sequestered. Nevertheless, the recombinant
ssembly system has proven very useful for understanding Gag’s
ntrinsic properties.
.3. Questions that remain to be answered in the recombinant
ag self-assembly system
In the future, it would be of interest to determine how “sponta-
eous” assembly of recombinant Gag is affected when the system is
ltered to more closely approximate the intracellular environment.
or example, how is the efﬁciency of assembly affected by reduc-
ng the concentration of recombinant Gag? Additionally, how does
nclusion of other proteins or RNP complexes (rather than puri-
ed RNA) affect the efﬁciency of recombinant Gag assembly? Given
hat facilitators of assembly are absent in the recombinant system,
ne might expect spontaneous assembly to occur only at extremely
igh concentrations of recombinant Gag, and that addition of RNP
omplexes as a source of RNA or addition of high concentrations of
ther proteins would reduce or eliminate spontaneous assembly.
Another question that arises is how recombinant Gag self-
ssembly is affected by mutations found to be critical for immature
apsid assembly in cells. As discussed in Section 2, the requirement
or speciﬁc residues in MA,  CA, and NC is an important hallmark
f Gag assembly under physiologically relevant conditions. An
xample of the discrepancy between assembly in cells and recom-
inant assembly is seen with the non-myristoylated Gag. In cells,
utations that inhibit myristoylation of Gag also inhibit assem-
ly (Bryant and Ratner, 1990; Gottlinger et al., 1989; Dooher et al.,
997), except in cases of signiﬁcant overexpression (Gelderblom
t al., 1987). However, in the recombinant assembly systemarch 193 (2014) 89–107
non-myristoylated Gagp6 is assembly competent, most likely
because the concentration-dependence that is a hallmark of assem-
bly in cells is not recapitulated by the in vitro assembly system. Thus,
these ﬁndings support the hypothesis that assembly takes different
pathways to a similar endpoint in these two systems. It would be
useful to examine whether other assembly-defective Gag mutants
assemble in the recombinant system. If they do, this would suggest
that other barriers to assembly in cells, besides low Gag concen-
tration, are not reproduced in the recombinant assembly system.
Differences in assembly phenotype between cells and the recom-
binant assembly system could be useful for understanding the role
of cellular facilitators of assembly, which HIV-1 may have evolved
to utilize in order to overcome barriers present only in the more
challenging intracellular environment.
5. Assembly of newly synthesized Gag using cell extracts
5.1. Cell-free assembly systems recapitulate the intracellular
environment
Like the recombinant assembly system, the cell-free system is
well suited for studying how biochemical manipulations affect Gag
assembly; however, unlike the recombinant assembly system, the
cell-free system recapitulates key features of the intracellular envi-
ronment. This is achieved through the use of cell extracts, such
as rabbit reticulocyte extract (Sakalian et al., 1996; Spearman and
Ratner, 1996) or wheat germ extract (Lingappa et al., 1997; Singh
et al., 2001; Zimmerman et al., 2002), and by linking Gag assem-
bly to translation. When comparing the cell-free and recombinant
assembly systems, ﬁve major differences should be noted (Fig. 4).
First, the cell-free assembly system begins with translation of Gag
from an mRNA (de novo Gag synthesis), while puriﬁed Gag pro-
teins in the recombinant assembly system are fully folded at the
start of the assembly reaction. Secondly, Gag proteins translated
in the cell-free system are full-length and myristoylated, rather
than myr(−) and p6. Thirdly, the cell-free system contains cel-
lular proteins while the recombinant system does not; in fact the
concentration of cellular protein in the cell-free system is as high
as 30–40 mg/ml. Additionally, the cell-free system contains much
lower concentrations of Gag, in the range of 10 ng/ml or 0.5 micro-
molar, which is 40 fold lower than the concentration of Gag  in
the recombinant assembly system (Lingappa et al., 2005). This
sub-micromolar Gag concentration is more likely to approximate
steady-state levels of Gag found in infected cells. Fourthly, mem-
branes are present in cell-free systems, allowing recapitulation of
membrane targeting of Gag, a critical feature of assembly in vivo.
Finally, in cell extracts as in cells, non-translating RNAs are likely to
be in RNP complexes within RNA granules, as discussed further in
Section 6.5.
5.2. Assembly in cell-free systems reproduces key features of
assembly in cells
In cell-free systems, the cellular extract provides all the cel-
lular factors needed for protein synthesis and post-translational
events, as well as membrane vesicles. Also added to the reaction
are an in vitro transcribed Gag mRNA that serves as the template
for translation, unlabeled and radiolabeled amino acids, an energy
regenerating system, and any critical cofactors that are removed
during preparation of the extract, such as myristoyl CoA, which is
needed for myristoylation. In a typical retroviral cell-free reaction,
Gag, the only viral protein present, is also the only protein that is
translated de novo; thus, newly synthesized Gag is radiolabeled,
while the cellular proteins in the reaction are unlabeled.
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During the 2 h cell-free reaction, Gag synthesis is followed
y post-translational events of assembly. Three approaches have
emonstrated that cell-free assembly of Gag closely mimics Gag
ssembly in cells (Lingappa et al., 1997). First, the Gag-containing
articles formed at the end of the reaction closely resemble HIV-
 immature capsids from cells in their size, shape, and density,
s judged by biochemical and ultrastructural analyses. Secondly,
ey features of the HIV-1 capsid assembly process in cells are
lso faithfully reconstituted in this system. For example, assembly
s inhibited at the same step by addition of detergents expected
o solubilize membrane vesicles at the start of the reaction, in
eactions that lack myristoyl CoA, and in reactions programmed
ith the G2A Gag mutant that fails to undergo myristoylation.
ogether, these ﬁndings suggest that assembly in the cell-free sys-
em requires myristate-dependent targeting of Gag to membranes,
s observed in cells. Thirdly, analysis of Gag mutants has revealed
hat phenotypes of assembly-competent and assembly-defective
ag mutants, originally identiﬁed in cells (see Section 2 above),
re faithfully reconstituted in the cell-free system (Lingappa et al.,
997; Singh et al., 2001). Thus, analyses of the end product, the
ssembly process, and phenotypes of Gag mutants conﬁrm that
he cell-free assembly system closely recapitulates the process of
ssembly that occurs in cells.
.3. Identiﬁcation of an energy-dependent, host-catalyzed
athway of assembly intermediates
One notable feature of the cell-free system is its inefﬁciency:
t best ∼30% of the newly synthesized Gag ends up as completed
apsids. This is likely attributable to the use of cell extracts, in
hich cellular proteins undergo progressive denaturation and are
ot replaced. Additionally, the heterologous nature of the system
ay  be a contributing factor, since the cell extracts that are used are
rom cells with a high synthetic capacity and few proteases, rather
han cells that HIV-1 evolved to infect efﬁciently. This inefﬁciency
urns out to be a strength of the cell-free system, since it allows
ntermediates in the assembly process to be trapped, identiﬁed,
solated, and analyzed. Such intermediates are found in extremely
mall quantities in human cells expressing Gag, where the assembly
rocess occurs much more efﬁciently. Indeed, their existence was
ot even hypothesized until they were ﬁrst revealed by studies in
he cell-free assembly system (Lingappa et al., 1997).
When cell-free assembly reactions were analyzed by veloc-
ty sedimentation, the ∼750S completed immature capsid was
bserved along with discrete Gag-containing complexes of smaller
izes: ∼10S, ∼80S, ∼150S, and ∼500S (Lingappa et al., 1997).
hile the cell-free assembly reaction is typically performed in
he absence of detergents to allow newly synthesized Gag to tar-
et to membrane vesicles, velocity sedimentation is performed
fter treating the reaction products with non-ionic detergents
hat solubilize membranes, thereby allowing analysis of Gag-
ontaining protein complexes that are free of membranes. Together
ulse-chase and mutational analysis established that the smaller
omplexes observed in the cell-free system represent true interme-
iates in the assembly process (Lingappa et al., 1997). Speciﬁcally,
ulse-chase experiments revealed that Gag proteins labeled dur-
ng a short radiolabeling “pulse” subsequently chase out of the
10S complex, ﬁrst into the ∼80S and ∼150S complexes and later
nto the ∼500S and ∼750S complexes. These experiments demon-
trated that the Gag-containing complexes were not dead-end “off
athway” side products but instead represent intermediates in a
athway that culminates in formation of the ∼750S completed
mmature capsid. Additionally, in the cell-free system, assembly-
efective Gag mutants identiﬁed in cellular systems were arrested
t speciﬁc points in the assembly pathway, accumulating only
hose intermediates that precede the point of blockade (Lingapparch 193 (2014) 89–107 99
et al., 1997; Singh et al., 2001), thereby conﬁrming the order of
intermediates in the pathway. Notably, after the approach for iden-
tifying these complexes was  developed in the cell-free system,
it was adapted to allow identiﬁcation of comparable assembly
intermediates in transfected and HIV-1 infected cells expressing
Gag (e.g. Dooher and Lingappa, 2004; Dooher et al., 2007; Lingappa
et al., 1997; Reed et al., 2012).
Studies also revealed that capsid assembly in the cell-free sys-
tem is energy-dependent, that ATP hydrolysis and not just ATP
binding was  likely required, and that the energy requirement
is post-translational and therefore separate from the well-
understood requirement for energy during translation (Lingappa
et al., 1997). This initiated a shift in thinking about Gag  assem-
bly. The “self-assembly” model has dominated the ﬁeld (and still
does, as revealed in textbooks, e.g. Hunter, 2013); but the ﬁnd-
ing that assembly is energy-dependent in cells implies that the
mechanism of assembly in cells differs from the spontaneous
assembly observed with recombinant Gag in vitro. This point was
subsequently underscored by additional studies demonstrating the
energy-dependence of retroviral capsid assembly in the cell-free
system and in cells (Dooher and Lingappa, 2004; Weldon et al.,
1998), and by the identiﬁcation of an ATP-binding protein, ABCE1,
that facilitates assembly in cells (Zimmerman et al., 2002). Likewise,
the ﬁnding that Gag assembles via a pathway of intermediates, in
the cell-free system and in cells, is also at odds with results of
recombinant assembly systems, in which no intermediates larger
than dimers have been identiﬁed (Ma  and Vogt, 2004). These con-
trasting models could be reconciled if Gag evolved the ability to
form assembly intermediates in cells to evade host innate immune
defenses and access cellular facilitators of assembly, as discussed
in Section 7.
5.4. Identiﬁcation of ABCE1, a cellular ATPase that facilitates
HIV-1 capsid assembly
Initial studies revealed that immature capsid assembly in the
cell-free system is dependent on one or more large host cell
complexes that could be removed from the system by ultracentrifu-
gation of the cell extract (Lingappa et al., 1997). Like the ﬁnding that
immature capsid assembly is energy-dependent, the suggestion
that cellular factors are critical for proper assembly of Gag did not
conform to expectations at the time. The subsequent identiﬁcation
of ABCE1, a cellular ATPase that facilitates assembly (Zimmerman
et al., 2002), helped to explain the dependence of assembly on
energy and cellular factors. ABCE1 is a cytoplasmic member of the
ATP-binding cassette (ABC) family of proteins (E1 subfamily) and
contains two nucleotide binding domains as well as two N-terminal
iron sulfur binding domains (Kerr, 2004). ABCE1 is associated with
Gag in the ∼80S, ∼150S, and ∼500S assembly intermediates (collec-
tively termed the high-molecular-mass assembly intermediates) in
both the cell-free system and in cells (Fig. 3) (Zimmerman et al.,
2002), but is not associated with Gag in the ∼10S fraction even
though ABCE1 and Gag are abundant in this fraction.
Importantly, capsid formation in the cell-free system was
inhibited when reactions were programmed with extracts immun-
odepleted of ABCE1. Conversely, when recombinant ABCE1 was
added back to the depleted extracts, capsid assembly was restored
(Zimmerman et al., 2002). In addition, a truncated ABCE1 mutant
containing only one of the two ATPase domains acted as a dom-
inant negative inhibitor of immature capsid assembly in cells
(Zimmerman et al., 2002). Together these studies provided strong
support for ABCE1 being a cellular facilitator of assembly. How-
ever, because ABCE1 is an essential protein, ABCE1 knockdown
leads to cell death within hours (Chen et al., 2006; Dooher et al.,
2007); thus, it has not been possible to test whether ABCE1 is criti-
cal for assembly in cells using siRNA knockdown approaches. Other
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tudies performed in cells have provided considerable information
bout ABCE1-containing intermediates (see Section 6.7) and iden-
iﬁed an additional ATP-dependent cellular facilitator of assembly,
DX6 (see Section 6.5).
.5. Strengths and limitations of the cell-free assembly system
The cell-free system provided the ﬁrst evidence that HIV-1 Gag
ssembly in cells proceeds through a stepwise, energy-dependent,
nd host-catalyzed pathway of intermediates. Assembly interme-
iates were readily identiﬁed in the cell-free system because it is
 closed system that does not recapitulate envelopment and virion
elease, its inefﬁciency results in accumulation of Gag in assembly
ntermediates, and it is easy to manipulate biochemically. Thus, the
ell-free system provided a “road map” for detection of assembly
ntermediates in cells, which are transient and present in very small
uantities. Additionally, the cell-free system is currently being used
s a screen for inhibitors of capsid assembly of a variety of viruses
Lingappa et al., 2013), and therefore holds promise for identifying
ovel antiviral small molecules in the future (see Section 6.4).
Notably, the heterologous nature of the cell-free system – in
hich the plant extracts support a virus that infects human cells –
s both a strength and weakness. Initially, the fact that HIV-1 cap-
ids could be assembled utilizing proteins from a plant extract was
uzzling to some since HIV-1 does not infect plants. However, it
ad long been known that immature capsids can be generated in
ower eukaryotes (Gheysen et al., 1989). Moreover, cellular facilita-
ors of assembly identiﬁed to date, e.g. ABCE1 and DDX6 (Reed et al.,
012; Zimmerman et al., 2002), are well conserved and likely func-
ion quite similarly to their homologues in human cells. A downside
o the cell-free system is that fewer tools are available for studying
roteins in wheat germ compared to human cells. For this reason –
nd to settle questions regarding the presence of the host-catalyzed
ssembly pathway in infected human cells – studies of the assem-
ly pathway in the past decade have been largely performed using
uman or non-human primate cell lines.
. Imaging, biochemical, and siRNA knockdown analyses of
ssembly in cells
.1. Live imaging of assembly in cells
In recent years, live imaging has been used to study many
spects of the HIV-1 life cycle, including genome packaging
reviewed in Moore and Hu, 2009), budding and release (reviewed
n Baumgartel et al., 2012), and cell-to-cell transmission (reviewed
n Campbell et al., 2008). Here we will conﬁne our discussion to
ow live cell imaging has been used to study assembly of Gag in
ells. Live imaging studies established that HIV-1 assembly occurs
rimarily at the PM,  with Gag going from undetectable to fully
ssembled in less than 10 min  (Ivanchenko et al., 2009; Jouvenet
t al., 2008, 2009). Fluorescence resonance energy transfer studies
onﬁrmed that Gag tagged with a ﬂuorescent protein undergoes
ultimerization at the PM (Jouvenet et al., 2008). Additionally, ﬂu-
rescent recovery after photobleaching allowed fully assembled
ites to be distinguished from assembling sites. Many of the highest
esolution live imaging studies use total internal reﬂection ﬂuores-
ent microscopy (TIR-FM), a method that only excites ﬂuorescent
roteins that are in close proximity to the coverslip, i.e. near the PM.
IR-FM analysis demonstrated that gRNA expressed alone moves
apidly, appearing only transiently at the PM,  while gRNA expressed
ith Gag was able to anchor at the PM (Jouvenet et al., 2009). Inhis study, Gag ﬂuorescence was initially observed ∼4.5 min  after
RNA appeared at the PM,  after which Gag ﬂuorescence increased,
onsistent with multimerization. Another live imaging study con-
rmed this conclusion by showing that accumulation of gRNA at thearch 193 (2014) 89–107
PM requires Gag (Kemler et al., 2010). Both studies proposed that
the Gag–gRNA association is likely initiated in the cytosol, and that
the number of Gag molecules in each membrane targeting event is
very small, below the level that can be detected using live imaging
(Jouvenet et al., 2009; Kemler et al., 2010). Subsequently, the initial
packaging complex inferred from live imaging studies was iden-
tiﬁed by immunoprecipitation of complexes containing Gag  and
gRNA from cell lysates (Kutluay and Bieniasz, 2010). Thus, based
on live imaging and biochemical studies of cells, it appears that
gRNA ﬁrst associates in the cytoplasm with a small number of Gag
proteins, possibly a dimer given results of crosslinking experiments
(Kutluay and Bieniasz, 2010).
While live imaging has greatly advanced our understanding
of the behavior of HIV-1 genomes near the PM and assembling
Gag in the late stages of multimerization, it is limited when pro-
teins of interest are expressed at concentrations that are below the
threshold for detection using this approach. For example, while a
study successfully detected ﬂuorescently tagged ALIX, a host pro-
tein involved in HIV-1 budding, by TIR-FM, the same study was
unable to detect ﬂuorescently tagged TSG101, a well-established
cellular factor critical for HIV-1 budding (Jouvenet et al., 2011b).
Additionally, it is difﬁcult to use live imaging to study early events
of assembly because diffuse background ﬂuorescence in the cytosol
reduces imaging resolution (Jouvenet et al., 2011a). In contrast, bio-
chemical and ultrastructural studies of assembly in cells expressing
HIV-1 proviruses are able to detect small amounts of Gag, both in
the cytoplasm and at the PM (Kutluay and Bieniasz, 2010; Reed
et al., 2012; Robinson et al., 2014); thus, these techniques nicely
complement live imaging studies.
6.2. Overview of cellular facilitators of assembly studied in cells
Broadly speaking, cellular factors critical for late events in the
HIV-1 life cycle act either during assembly, RNA encapsidation,
budding, or release. The majority of such factors identiﬁed to date
function during budding and release. These include TSG101, ALIX,
ESCRTIII proteins, and VPS4 (reviewed in Votteler and Sundquist,
2013). Here we  focus on the smaller number of factors shown to
facilitate immature capsid assembly per se.  The best understood
among them is PI(4,5)P2, which acts during membrane targeting
of assembling Gag and will be described ﬁrst. Next we will discuss
cellular studies of ABCE1 and DDX6, both of which appear to facil-
itate Gag assembly. Finally, we  will brieﬂy discuss Staufen, an RNA
binding protein that has been implicated in Gag translation, mul-
timerization, and gRNA packaging (Chatel-Chaix et al., 2004, 2007,
2008; Dugre-Brisson et al., 2005; Milev et al., 2010); AP-3, a cellular
factor involved in endosome recycling that inﬂuences Gag trafﬁc-
king (Dong et al., 2005; Garcia et al., 2005; Kyere et al., 2012; Liu
et al., 2012); and N-Ethylmaleimide-sensitive Factor Attachment
Protein Receptor (SNARE) machinery (Joshi et al., 2011).
6.3. PI(4,5)P2 facilitates proper membrane targeting and
myristate exposure
Assembling Gag targets primarily to the PM rather than to other
cellular membranes (Jouvenet et al., 2006) because of its interaction
with PI(4,5)P2, an anionic lipid that is found primarily in the cyto-
plasmic leaﬂet of the PM.  PI(4,5)P2 plays two roles during assembly,
acting to target assembling Gag speciﬁcally to the PM and also
facilitating myristate exposure (reviewed in Chukkapalli and Ono,
2011). While a role in assembly for compounds related to phos-
phoinositides was ﬁrst suggested by studies in the recombinant
Gag assembly system (Campbell et al., 2001), deﬁnitive evidence
for this role came from knockdown studies in cells. When PI(4,5)P2
was depleted from cells using siRNA directed against a kinase crit-
ical for PI(4,5)P2 biogenesis, virus particle release was  signiﬁcantly
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educed (Ono and Freed, 2004). This study also demonstrated that
edirecting PI(4,5)P2 to internal compartments rather than the PM
aused assembling Gag to be mislocalized, with resulting reduc-
ions in virus release. Thus, it is clear that PI(4,5)P2 is critical for
argeting assembling Gag to the PM through the results of cellu-
ar studies (Chukkapalli et al., 2008; Monde et al., 2011; Ono et al.,
004), as well as structural studies that delineated the binding sites
or PI(4,5)P2 in MA (Saad et al., 2006; Shkriabai et al., 2006).
.4. ABCE1, the ﬁrst cellular facilitator of assembly to be identiﬁed
As described in Section 5.4, ABCE1, the ﬁrst host protein found
o facilitate Gag assembly was initially identiﬁed in the cell-
ree system (Zimmerman et al., 2002; reviewed in Stevenson,
003). Because siRNA depletion of ABCE1 causes rapid cell death,
nockdowns have not been useful for understanding the func-
ion of ABCE1 during assembly. However, other studies – including
epletion-reconstitution studies in the cell-free system and domi-
ant negative studies in cells – point strongly to an important role
or ABCE1 during Gag assembly (Zimmerman et al., 2002). Inter-
stingly, two ﬁndings suggest that ABCE1 binds Gag directly, in an
NA-independent manner, to a region in Gag other than NC. First,
inding of Gag to endogenous ABCE1 in cells is resistant to RNase
 treatment (Lingappa et al., 2006). Secondly, in coimmunoprecip-
tation experiments, ABCE1 binds to GagZip chimeras (Klein et al.,
011), in which NC has been replaced with a leucine zipper that
romotes protein–protein interactions but does not bind to nucleic
cid. Thus, ABCE1 differs from many Gag binding factors, including
POBEC3G (e.g. Schafer et al., 2004; Zennou et al., 2004) and Staufen
Milev et al., 2012), which bind indirectly to the Gag NC domain via
NA.
Recently, the lethality of ABCE1 knockdowns has been explained
y the ﬁnding that ABCE1 is critical for coupling translation termi-
ation to ribosome recycling (Barthelme et al., 2011; Becker et al.,
012; Khoshnevis et al., 2010; Pisarev et al., 2010; Shoemaker and
reen, 2011), and likely promotes splitting the 40S and 60S ribo-
omal subunits (reviewed in Hopfner, 2012; Nurenberg and Tampe,
013). The critical role for ABCE1 in ribosome disassembly also
xplains why ABCE1 is exceptionally well conserved, present in all
ukaryotes and all archaebacteria studied to date (Chen et al., 2006).
BCE1 was initially identiﬁed as an inhibitor of RNase L (Bisbal
t al., 1995), however RNase L inhibition is not a conserved func-
ion of ABCE1 given that the phylogenetic distribution of ABCE1 is
uch broader than that of RNase L (Kerr, 2004). Crystal structure
f archaebacterial ABCE1 reveals it to be a clamp-shaped protein
hat undergoes an impressive degree of tweezer-like movement
Karcher et al., 2005, 2008). To date, the function of ABCE1 in
IV-1 capsid assembly has remained elusive; however, studies in
ells have added considerably to our understanding of how Gag
rogresses through ABCE1-containing assembly intermediates (see
ection 6.7).
Studies also suggest a possible role for ABCE1 in replication of
ther viruses. A small molecule screen based on a cell-free system
or assembly of rabies virus capsids identiﬁed a compound that
nhibits replication of infectious rabies virus. Interestingly, this rel-
tively non-toxic inhibitor targets a subfraction of ABCE1 (Lingappa
t al., 2013). Thus, ABCE1 may  play a broad role in viral replica-
ion, and could be a target for antiviral compounds that selectively
nhibit its action in viral replication. Additionally, studies suggest
hat ABCE1 may  be under positive selection (Crawford et al., 2009).
hile the sample size of HIV-1 infected vs. uninfected individuals
n this study was insufﬁcient to conclude whether rare variation
n ABCE1 inﬂuences outcomes, a separate study found that HIV-1
eplication in CD4+ T cells was markedly reduced in three het-
rozygotes carrying a deletion in the ABCE1 3′ UTR (Bleiber et al.,
005).rch 193 (2014) 89–107 101
6.5. DDX6 promotes immature capsid formation in an
ATP-dependent manner
The DEAD-box RNA helicase DDX6 ﬁrst came to the atten-
tion of retrovirologists because of the yeast retrotransposon Ty3
(Beliakova-Bethell et al., 2006), which shares a common ancestor
with retroviruses (Pelisson et al., 1997). Studies in yeast demon-
strated that P body proteins, including the yeast DDX6 homologue
Dhh1, are required for Ty3 retrotransposition (Aye et al., 2004;
Irwin et al., 2005) and are associated with assembling Ty3 Gag
(Beliakova-Bethell et al., 2006). P bodies are a subclass of RNA gran-
ules, which are sites of RNA metabolism to which cellular mRNAs
are sent for silencing, storage, and degradation in healthy cells –
i.e. for everything besides translation (reviewed in Anderson and
Kedersha, 2006). Cellular proteins in RNA granules include enzymes
that facilitate events in RNA metabolism, for example RNA helicases
like DDX6 that enable RNP remodeling, a process in which one set of
proteins coating an RNA are replaced with another set of proteins.
Since the fate of RNA is typically dictated by associated proteins
in the RNP complex (reviewed in Lee and Lykke-Andersen, 2013),
enzymes like RNA helicases could have a profound inﬂuence on the
efﬁciency of Gag assembly and encapsidation in cells.
Using siRNA knockdown approaches, DDX6 was  found to facili-
tate events in HIV-1 assembly independent of RNA packaging (Reed
et al., 2012). Like ABCE1, DDX6 was  associated with all the high-
molecular-mass assembly intermediates, as were other P body
proteins, including AGO2 and DCP2. In this study, quantitative EM
analyses found that DDX6 acts at or after targeting of Gag to the
PM (Fig. 3). Moreover, DDX6 knockdowns were rescued with WT
DDX6 but not with a DDX6 mutant incapable of ATP hydrolysis,
indicating that DDX6 acts enzymatically during assembly. Addi-
tionally, this study also showed that in uninfected cells, DDX6 is
present in a complex with ABCE1 and AGO2, termed the precursor
complex (Fig. 4 in Reed et al., 2012). Thus, it appears that newly
synthesized Gag co-opts the precursor complex to form the ∼80S
assembly intermediate. Notably, the precursor complex is smaller
than a typical P body, and P bodies have not yet been found to con-
tain ABCE1. Hence, the precursor complex present in uninfected
cells may  represent a unique subclass of RNA granules that differ
in size from P bodies, but are similar to P bodies in composition
except for the presence of ABCE1 (Reed et al., 2012).
Why  HIV-1 Gag co-opts this unique subclass of host RNA gran-
ules remains to be determined, but two  possible explanations make
intuitive sense. First, because RNA helicases remodel RNPs, they lib-
erate RNAs from one set of proteins, allowing them to be replaced
by a new set of proteins that dictate a different function (reviewed
in Lee and Lykke-Andersen, 2013). Thus, co-opting host RNA heli-
cases during assembly could allow the virus to reprogram gRNA
and/or cellular mRNAs involved in translation to function as nucle-
ators of assembly. A second reason for HIV-1 Gag to co-opt host RNA
granules is to access gRNA that is sequestered within RNA granules
to evade innate immune defenses. Thus, sequestration of gRNA and
assembling Gag in RNA granule-like assembly intermediates could
serve the dual purpose of allowing access to enzymatic facilita-
tors of capsid assembly, while at the same time concealing viral
components from the host immune response. In support of this,
recent studies in chronically infected T cells reveal that HIV-1 gRNA
is present in ABCE1- and DDX6-containing high-molecular-mass
assembly intermediates (Robinson et al., 2014), along with Gag.
6.6. Staufen1, AP-3ı, and SNARE machinery: additional cellular
factors implicated in late eventsAnother cellular factor that is implicated in late events is
Staufen1, a cellular double-stranded RNA binding protein. Unlike
ABCE1, Staufen1 binds to Gag indirectly, via RNA (Abrahamyan
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Fig. 5. Double immunogold labeling shows enrichment of ABCE1 at sites of WT  Gag
assembly at the PM of HIV-1 infected cells. HIV-1-infected COS-1 cells expressing
WT  Gag or an assembly-incompetent MACA mutant were analyzed by immuno-
gold double-label EM,  using antibodies to Gag (small gold) and ABCE1 (large gold).
Images were chosen to reﬂect previous quantitative immunolabeling studies that
show signiﬁcant recruitment of ABCE1 to WT Gag assembly sites at the PM,  versus
low  levels of background ABCE1-Gag colocalization with the MACA mutant (Reed
et  al., 2012). (A) Six late WT assembly sites, half of which colocalize with ABCE1.
(B) Three early WT assembly sites, all of which colocalize with ABCE1. (C) PMs  of
two  adjacent cells expressing assembly-incompetent, membrane targeted MACA,
displaying low background levels of ABCE1. Scale bars, 200 nm.02 J.R. Lingappa et al. / Viru
t al., 2010; Chatel-Chaix et al., 2004, 2007, 2008; Dugre-Brisson
t al., 2005; Milev et al., 2010, 2012; Mouland et al., 2000). While
verexpression of Staufen1 inhibits virus infectivity and enhances
RNA packaging (Mouland et al., 2000), Staufen1 knockdown also
nhibits virus infectivity (Chatel-Chaix et al., 2004). Additionally,
taufen1 has been reported to play a role in Gag translation (Dugre-
risson et al., 2005) and multimerization (Chatel-Chaix et al., 2004,
008). Thus, Staufen1’s role appears to be complex, and exactly
ow it acts during assembly remains to be determined. Notably,
taufen1 is found in association with ABCE1 (Milev et al., 2012),
aising the possibility that Staufen is part of the aforementioned
recursor complex, as well as the high-molecular-mass assembly
ntermediates.
The AP-3 subunit, which is part of the AP-3 complex involved
n endosomal-lysosomal sorting (Dell’Angelica, 2009), has been
eported to bind to Gag in an MA-dependent manner and facili-
ate HIV-1 particle production. These studies used knockdown and
ominant-negative experiments in 293T cells (Dong et al., 2005),
s well as analysis of cells that are genetically deﬁcient in AP-3
Liu et al., 2012). However, studies have shown that released virus
an be endocytosed in HIV-1 expressing 293T cells (Jouvenet et al.,
006). Since AP-3 acts during endosomal-lysosomal sorting, the
ossibility that AP-3 affects virus production by modulating endo-
ytosis of released virus will need to be explored further. These
uestions are underscored by a recent study reporting that AP-3
oes not bind directly to myr(−)MA, and concluding that the effects
f AP-3 in virus assembly remain unclear (Kyere et al., 2012).
Finally, SNARE proteins, which are involved in vesicle fusion
nd regulation of vesicular trafﬁcking, have also been implicated in
embrane targeting of assembling Gag, through siRNA and domi-
ant negative studies (Joshi et al., 2011). It remains unclear whether
hese proteins act directly, or indirectly through effects on other
ellular factors such as PI(4.5)P2 (Garg and Joshi, 2012).
.7. Biochemical approaches to studying capsid assembly
ntermediates in cells
Biochemical studies of assembly intermediates have led to
nsights into how assembly proceeds in cells. Cells that are HIV-1
nfected or transfected to express HIV-1 or other primate lentivi-
al Gag proteins (SIVmac, SIVagm, or HIV-2) contain complexes
imilar in size and composition to the assembly intermediates
nitially identiﬁed in the cell-free system (Dooher and Lingappa,
004). In cells, as in the cell-free system, enzymatic depletion
f ATP results in accumulation of the ∼80S complex (Dooher
nd Lingappa, 2004). Conﬁrmation that the Gag-containing com-
lexes are assembly intermediates has come from pulse-chase
xperiments in cells expressing the HIV-1 provirus (Dooher et al.,
007). Additionally, critical Gag mutations have been examined
or their effects on the assembly pathway, and each has been
ound to inhibit the assembly at one of the ﬁve speciﬁc points
n the pathway in human 293T cells, with accumulation of only
he assembly intermediates that precede the point of blockade
Class 1–5 mutants in Fig. 3) (Dooher and Lingappa, 2004; Klein
t al., 2011; Lingappa et al., 1997; Robinson et al., 2014). Thus,
 wealth of data support the notion that Gag assembles through
 stepwise pathway of assembly intermediates in cells. Studies
hat employed other biochemical approaches have also detected
imilar Gag-containing complexes in cells (Holm et al., 2003;
ee et al., 1999; Lee and Yu, 1998; Morikawa et al., 2004; Tritel
nd Resh, 2000). Despite extensive evidence for their existence,
ssembly intermediates in cells are understudied, in large part
ecause they are technically difﬁcult to identify for a number
f reasons. First, they are present in small quantities because
hey rapidly progress to the next step in the pathway; secondly,
ag epitopes are known to be masked as Gag multimerizes at
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he PM (Ono et al., 2005) making it difﬁcult to isolate assembly
ntermediates using Gag antibodies; and thirdly, endocytosis of
eleased virus in many commonly used cell lines (e.g. 293T cells)
esults in large ∼750S signals from intracellular completed capsids
hat overwhelm smaller signals from the assembly intermediates
n velocity sedimentation gradients (Robinson et al., 2014).
The high-molecular-mass assembly intermediates in cells con-
ain Gag, gRNA, and the viral proteins GagPol and Vif (Dooher et al.,
007; Robinson et al., 2014; Zimmerman et al., 2002). Notably,
agPol is present in a 1:20 ratio relative to Gag in the assembly
ntermediates (Dooher et al., 2007), as would be expected from the
fﬁciency of ribosomal frameshifting (Jacks et al., 1988). In addi-
ion, immunoprecipitation with ABCE1 antibody reveals that these
omplexes contain cellular factors, including ABCE1 and the RNA
ranule proteins DDX6, AGO2, and DCP2 (Dooher and Lingappa,
004; Dooher et al., 2007; Klein et al., 2011; Lingappa et al., 2006;
eed et al., 2012; Robinson et al., 2014; Zimmerman et al., 2002).
hese ﬁndings were conﬁrmed by quantitative immunogold label-
ng, which demonstrated that ABCE1 and DDX6, the two cellular
roteins in the intermediates that facilitate assembly (Reed et al.,
012; Zimmerman et al., 2002), are enriched in early and late
ites of Gag assembly at the PM (Dooher et al., 2007; Reed et al.,
012) (Fig. 5). The subcellular localization of speciﬁc assembly
ig. 6. A model for the temporal sequence of CA-CA interactions during assembly of HIV-
 mutants in Fig. 3) are identical to, or in close proximity with, residues that form CA-CA
PMV  CA-NC (Bharat et al., 2012; Robinson et al., 2014). If one assumes that each interface
lockade data from Fig. 3 can be used to generate a map  of when key CA-CA interfaces mig
2014), which proposes that formation of the inter-hexameric CA-CTD dimer interface (inv
o  membranes; and that formation of the CA-CTD intra-hexameric interface (involving r
ast  the ∼80S membrane-associated intermediate. These inter- and intra-hexameric CA-
rowing capsid during multimerization at the PM.  Finally, for a stable ∼500S assembly int
e  required (using residues in CA helices 4–6). Colors as in Fig. 2.rch 193 (2014) 89–107 103
intermediates has also been determined using membrane ﬂotation
analysis of cells expressing the HIV-1 provirus (Robinson et al.,
2014). While the ∼10S and ∼80S assembly intermediates are found
in the cytoplasm, the ∼80S, ∼500S, and ∼750S intermediates are
found primarily at the PM (Robinson et al., 2014; Fig. 3). The
presence of the ∼80S intermediate in both subcellular locations
suggests that this may  be the intermediate that takes assembling
Gag from the cytoplasm to the PM.  Consistent with this possibility,
non-myristoylated Gag mutants, which fail to target to the PM,  are
arrested as cytoplasmic ∼80S assembly intermediates. However,
both EM and membrane ﬂotation experiments suggest that some
∼10S Gag is also present at the PM,  but not in association with
cellular factors. Thus, the data argue for a model in which two
populations of Gag are found at the PM:  one that is anchored at the
PM,  initiates assembly, and is associated with gRNA, ABCE1, and
DDX6; and another consisting of ∼10S Gag proteins that are not
associated with ABCE1 or DDX6 and could move laterally in the PM
to add subunits to the anchored site of assembly during multimeri-
zation (Robinson et al., 2014; Fig. 3). This model is consistent with
conclusions from live imaging studies (Jouvenet et al., 2008, 2009)
but will require further testing to be validated. Notably, unlike
other cellular proteins (Chertova et al., 2006), ABCE1 and DDX6
are not found in released virions, suggesting that these cellular
1 Gag in cells. Critical residues in CA that are required for assembly (Class 3, 4, and
 interfaces in a recent high-resolution structure of the immature capsid formed by
 is formed at the step when the relevant residues are required during assembly, the
ht form during cells. The diagram shows such a model, adapted from Robinson et al.
olving residues in CA helix 9) is required for the ∼80S intermediate to stably target
esidues in the CA-CTD crystallographic base) may  be required for Gag  to progress
CTD contacts may  be formed in repeated rounds, as additional Gag is added to the
ermediate to be produced, formation of the inter-hexameric CA-NTD interface may
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acilitators of assembly dissociate from the immature capsid after
ssembly is completed (Dooher et al., 2007; Reed et al., 2012).
.8. Correlating biochemical studies of assembly in cells to
dvances in structural biology
Because pulse-chase and mutational analyses have identiﬁed
he temporal sequence in which capsid assembly intermediates are
ormed in cells, the assembly pathway can also be used to map  the
oint of action in the pathway of residues critical for Gag assem-
ly (Fig. 3). Studies show that the NC basic residues are required
t the ﬁrst step of the assembly pathway, enabling progression
rom the unassembled ∼10S intermediate to the ∼80S intermediate
Lingappa et al., 2006), while residues required for myristoylation
nd myristate exposure (at the extreme N-terminus of MA)  act next,
eing required for membrane targeting of the ∼80S intermediate
Robinson et al., 2014). After that, residues in the CA-CTD dimer
nterface (in CA-CTD helix 9) are required for formation of a sta-
le membrane-bound ∼80S intermediate, while critical residues in
he CA-CTD base are required for progression past the membrane-
ound ∼80S intermediate. Finally critical residues in the CA-NTD
4-6 region act at the end of the pathway, being required for
rogression beyond the membrane-associated ∼500S intermediate
Robinson et al., 2014) (Fig. 3).
Interestingly, many of the CA residues found to be critical for
rogression of Gag through each step of the assembly pathway are
lso found at CA-CA interfaces in the fully assembled immature
apsid (Bharat et al., 2012, 2014; Robinson et al., 2014). Given that
he main function of CA is thought to be formation of CA-CA inter-
aces, mutation of residues at each interface might be expected to
lock assembly at the speciﬁc step where that critical interface is
ormed. If one makes this assumption, then a model can be pro-
osed for when speciﬁc CA-CA interfaces form based on the point
f arrest of these mutants in the assembly pathway (Robinson et al.,
014). In this model, inter-hexameric CA-CTD contacts are required
or formation of a stable membrane-associated ∼80S intermediate;
ntra-hexameric CA-CTD contacts must be formed for progression
ast the membrane-associated ∼80S intermediate; and CA-NTD
ontacts must be formed for progression past the membrane-
ssociated ∼500S intermediate (Robinson et al., 2014; Fig. 6). While
his model is speculative, it is based on reasonable assumptions
nd provides a framework for understanding events that may  be
ccurring at each step of the assembly pathway.
. Concluding remarks and future directions: reconciling
ifferent models of assembly
In this review, we summarized conclusions regarding HIV-1
ssembly and described the experimental approaches that led to
hem. There is general consensus for conclusions obtained using
any of these approaches, such as mutational analysis and live
maging. Likewise, in the area of structural biology, there is consid-
rable agreement. In other areas of the assembly ﬁeld, consensus
as not yet been reached. Perhaps the most striking example of
ontroversy is the model of host-catalyzed assembly supported
y studies in the cell-free system and in cells, which contrasts
tarkly with the well-established model of spontaneous assembly
f puriﬁed recombinant Gag. On the surface, these two  models
ppear to be at odds, but a more careful analysis of the underlying
oncepts suggests ways of reconciling them. Speciﬁcally, both
odels make sense if the ability to self-assemble is necessary for
ssembly, but not sufﬁcient for assembly in the intracellular envi-
onment where the virus encounters innate immune defenses and
nergetic barriers not present in the simpliﬁed environment of the
ecombinant assembly system. In the intracellular environment,arch 193 (2014) 89–107
the underlying principles revealed by the recombinant assembly
system still hold: i.e. assembly is initiated by dimerization of Gag,
oligomerization of Gag is nucleated by RNA, and Gag has an intrin-
sic ability to form Gag–Gag interactions. However, the intracellular
environment likely complicates each of these basic features of
assembly, potentially leading to the evolution of viral mechanisms
for overcoming these intracellular barriers. For example, studies
suggest that to ﬁnd nucleating RNA in an environment where RNAs
are coated with RNPs, the virus may  have evolved mechanisms
for co-opting helicases that remodel RNPs; likewise, to evade host
immune defenses, the virus may  sequester gRNA within host RNA
granules, which Gag must enter to access RNA and RNA helicases.
Additionally, we speculate that to avoid the unfavorable energetics
of unfolding “folded-over” monomeric Gag, the virus may  have
evolved to utilize cellular chaperones to retain Gag in an extended
conformation and promote dimerization.
Note that assembly in cells is considerably more complex than
assembly in the simpliﬁed recombinant assembly system. Thus,
more work will need to be done to advance our primitive under-
standing of how cellular facilitators function during assembly –
and in the process controversial ideas and technically challenging
approaches will need to be considered, explored, and patiently
pursued. Importantly, as our knowledge of intracellular events
in assembly advances, more pieces of the puzzle are falling into
place. As an example, ﬁndings in a recent temporal analysis of
events that occur at each step of the host-catalyzed assembly
pathway corresponded surprisingly well with results of previous
structural, mutational, and live imaging studies (Robinson et al.,
2014). Future studies coordinating data from the various experi-
mental approaches discussed herein will likely lead to even more
integration of different models of HIV-1 assembly.
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